Koh Y Y, Park Y, Jeong J H, Kim C K, Min Y G, Chi J G
Department of Pediatrics, Seoul National University Hospital, Seoul, Korea.
Chest. 2000 Feb;117(2):427-33. doi: 10.1378/chest.117.2.427.
There is growing evidence that regular beta(2)-agonist use in patients with asthma is associated with decreased airway caliber and increased bronchial responsiveness. The aim of this study was to determine whether regular treatment with beta(2)-agonists induces changes in lung function and bronchial responsiveness in patients with primary ciliary dyskinesia.
A randomized, double-blind, placebo-controlled, crossover study.
Nineteen children with primary ciliary dyskinesia.
Subjects received inhaled salbutamol or identical placebo (2 x 100 microg qid) for periods of 6 weeks with a wash-out period of 4 weeks.
FEV(1) was measured before and 3 weeks and 6 weeks after salbutamol or placebo treatment. High-dose methacholine inhalation tests were performed before and 6 weeks after each treatment. The provocative concentration of methacholine producing a 20% fall in FEV(1) (PC(20)) and maximal airway narrowing (MDeltaFFEV(1)) was measured. No significant change in FEV(1) was observed during the salbutamol or placebo periods. No significant differences in the parameters of bronchial responsiveness (PC(20) and MDeltaFFEV(1)) were noted as the result of either salbutamol or placebo treatment.
Our data have shown that salbutamol, inhaled regularly for 6 weeks, did not cause either a decline in lung function or an increase in bronchial responsiveness in subjects with primary ciliary dyskinesia.
越来越多的证据表明，哮喘患者定期使用β2受体激动剂与气道口径减小和支气管反应性增加有关。本研究的目的是确定β2受体激动剂的常规治疗是否会引起原发性纤毛运动障碍患者肺功能和支气管反应性的变化。
一项随机、双盲、安慰剂对照的交叉研究。
19名原发性纤毛运动障碍儿童。
受试者接受吸入沙丁胺醇或相同的安慰剂（2×100微克，每日4次），为期6周，洗脱期为4周。
在沙丁胺醇或安慰剂治疗前、治疗后3周和6周测量第一秒用力呼气容积（FEV1）。在每次治疗前和治疗后6周进行高剂量乙酰甲胆碱吸入试验。测量使FEV1下降20%的乙酰甲胆碱激发浓度（PC20）和最大气道狭窄（MDeltaFFEV1）。在沙丁胺醇或安慰剂治疗期间，未观察到FEV1有显著变化。沙丁胺醇或安慰剂治疗后，支气管反应性参数（PC20和MDeltaFFEV1）均无显著差异。
我们的数据表明，在原发性纤毛运动障碍患者中，定期吸入沙丁胺醇6周，既不会导致肺功能下降，也不会导致支气管反应性增加。
